CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (IBRX) (NASDAQ: IBRX), a leading immunotherapy company, today announced new paradigm changing findings from the Phase 2 QUILT-3.055 study, ...
Lyell Immunopharma, Inc. announced promising clinical data for its CAR T-cell therapy candidate LYL314, showing an 88% overall response rate and a 72% complete response rate in patients with relapsed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results